Загрузка...
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction wi...
Сохранить в:
Опубликовано в: : | Blood |
---|---|
Главные авторы: | , , , , , , , , , , , , , , , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
American Society of Hematology
2016
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4920022/ https://ncbi.nlm.nih.gov/pubmed/27069256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-688796 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|